Phase I Study to Evaluate the Tolerability, Pharmacokinetics, Immunogenicity, Safety of Dose Escalation and Preliminary Efficacy of GR1401 in Patients with Advanced Solid Tumors

Trial Profile

Phase I Study to Evaluate the Tolerability, Pharmacokinetics, Immunogenicity, Safety of Dose Escalation and Preliminary Efficacy of GR1401 in Patients with Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs GR 1401 (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Sponsors Genrix (Shanghai) Biopharmaceuticals
  • Most Recent Events

    • 08 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top